The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs

被引:53
作者
Hendset, M. [1 ]
Haslemo, T. [1 ]
Rudberg, I. [1 ]
Refsum, H. [1 ]
Molden, E. [1 ]
机构
[1] Diakonhjemmet Hosp, Dept Psychopharmacol, N-0319 Oslo, Norway
关键词
D O I
10.1055/s-2006-946701
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In therapeutic drug monitoring (TDM) practice of psychotropic agents, it is common to summarize plasma concentrations of parent drugs and metabolites when these are considered equipotent. However, there is no clear definition of the term equipotent and one should be aware that metabolites referred to as equipotent in the literature could display several-fold differences in affinities toward target proteins. The fact that the parent drug and metabolite may have different abilities to penetrate the blood-brain-barrier further complicates the picture. Potential differences in brain distribution imply that various metabolite/drug ratios representing the same total concentration in plasma reflect different active concentrations in the brain. Plasma metabolite/drug ratios could differ extensively according to metabolic phenotype and administration route. An example is risperidone where the plasma metabolite/drug ratio is 30-fold lower in cytochrome P450 2D6 poor metabolizers compared to ultrarapid metabolizers, and four-fold lower after intramuscular compared to oral administration. As risperidone is more lipophilic and less effluxed by P-glycoprotein in the blood-brain-barrier than the active metabolite 9-hydroxyrisperidone, one might speculate that patients with high plasma metabolite/drug ratios obtain lower active concentrations in the brain. However, the relative drug-metabolite brain distribution needs to be quantified in humans to clarify to what degree drug and metabolite plasma levels reflect active brain concentrations. The present review illustrates the complexity of active metabolites in TDM with focus on amitriptyline, clomipramine, doxepin, imipramine, fluoxetine, venlafaxine and risperidone, all psychotropic drugs where target plasma concentration ranges are based on the sum of parent drug and metabolite. In addition, perspectives on the possibility of using distribution- and activity-weighted plasma concentrations are provided.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 59 条
[1]   Investigation of terbinafine as a CYP2D6 inhibitor in vivo [J].
Abdel-Rahman, SM ;
Gotschall, RR ;
Kauffman, RE ;
Leeder, JS ;
Kearns, GL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :465-472
[2]   CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations [J].
Alfaro, CL ;
Lam, YWF ;
Simpson, J ;
Ereshefsky, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :58-66
[3]   Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats [J].
Aravagiri, M ;
Marder, SR .
PSYCHOPHARMACOLOGY, 2002, 159 (04) :424-431
[4]   DEXTROMETHORPHAN AND MEPHENYTOIN PHENOTYPING OF PATIENTS TREATED WITH THIORIDAZINE OR AMITRIPTYLINE [J].
BAUMANN, P ;
MEYER, JW ;
AMEY, M ;
BAETTIG, D ;
BRYOIS, C ;
JONZIERPEREY, M ;
KOEB, L ;
MONNEY, C ;
WOGGON, B .
THERAPEUTIC DRUG MONITORING, 1992, 14 (01) :1-8
[5]   The AGNP-TDM expert group consensus guidelines:: Therapeutic Drug Monitoring in psychiatry [J].
Baumann, P ;
Hiemke, C ;
Ulrich, S ;
Eckermann, G ;
Gaertner, I ;
Gerlach, M ;
Kuss, HJ ;
Laux, G ;
Müller-Oerlinghausen, B ;
Rao, ML ;
Riederer, P ;
Zernig, G .
PHARMACOPSYCHIATRY, 2004, 37 (06) :243-265
[6]   AMITRIPTYLINE PHARMACOKINETICS AND CLINICAL-RESPONSE .2. METABOLIC POLYMORPHISM ASSESSED BY HYDROXYLATION OF DEBRISOQUINE AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M ;
KOEB, L ;
KUPFER, A ;
TINGUELY, D ;
SCHOPF, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (02) :102-112
[7]  
BENFIELD DP, 1980, POSTGRAD MED J, V56, P13
[8]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[9]   The role of noradrenaline and selective noradrenaline reuptake inhibition in depression [J].
Brunello, N ;
Mendlewicz, J ;
Kasper, S ;
Leonard, B ;
Montgomery, S ;
Nelson, JC ;
Paykel, E ;
Versiani, M ;
Racagni, G .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 (05) :461-475
[10]   The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation [J].
de Leon, J ;
Susce, MT ;
Pan, RM ;
Fairchild, M ;
Koch, WH ;
Wedlund, PJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) :15-27